SSY Group (HK:2005) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Cycloserine Capsules and Lornoxicam for injection. Cycloserine Capsules are aimed at treating tuberculosis and urinary tract infections, while Lornoxicam injections target acute pain management. These approvals mark a significant step in SSY Group’s product development strategy.
For further insights into HK:2005 stock, check out TipRanks’ Stock Analysis page.
